Search results for "Anticoagulant therapy"

showing 10 items of 22 documents

Ischemic stroke risk during long-term follow up in patients with successful catheter ablation for atrial fibrillation in Korea

2018

The interruption of oral anticoagulation therapy (OAC) after CA of atrial fibrillation (AF) is controversial. The purpose of this study was to evaluate the relationship between successful long-term outcomes of catheter resection and SR maintenance and ischemic stroke risk in Korea. We studied 1,548 consecutive patients who were followed up for more than 2 years after CA of AF. We investigated the incidence of ischemic stroke during long-term follow-up. Compared to the AF recurrence group (n = 619), the sinus rhythm (SR) maintenance group (n = 929) had more paroxysmal AF (74.6% versus 44.4%, p<0.001), smaller LA size (39.9±5.7mm versus 42.3±6.0mm, p<0.001), and younger age (54.2±10.9 years v…

Malemedicine.medical_treatmentAnticoagulant Therapylcsh:Medicine030204 cardiovascular system & hematologyAntiplatelet TherapyPathology and Laboratory MedicineVascular MedicineBrain IschemiaGeographical LocationsElectrocardiography0302 clinical medicineRisk FactorsAtrial FibrillationMedicine and Health SciencesMedicineSinus rhythm030212 general & internal medicinelcsh:ScienceMultidisciplinaryPharmaceuticsIncidence (epidemiology)IncidenceAtrial fibrillationMiddle AgedStrokeCatheterCardiovascular TherapyBioassays and Physiological AnalysisNeurologyCardiologyCatheter AblationFemaleArrhythmiaResearch ArticleBiotechnologymedicine.medical_specialtyCathetersAsiaLong term follow upCerebrovascular DiseasesCardiologyCatheter ablationHemorrhageResearch and Analysis Methods03 medical and health sciencesSigns and SymptomsDrug TherapyDiagnostic MedicineInternal medicineRepublic of KoreaHumansIn patientIschemic StrokeKoreabusiness.industrylcsh:RElectrophysiological TechniquesBiology and Life Sciencesmedicine.diseaseIschemic strokePeople and Placeslcsh:QMedical Devices and EquipmentCardiac ElectrophysiologybusinessFollow-Up StudiesPLoS ONE
researchProduct

Residual vein thrombosis and D-dimer for optimizing duration of anticoagulation in idiopathic deep vein thrombosis.

2010

Long-term anticoagulant treatment is highly effective in preventing recurrent Venous Thrombo-Embolism (VTE) in patients with idiopathic Deep Vein Thrombosis (DVT) of the lower limbs, though associated with an increased risk for major bleeding that may offset the benefits of anticoagulation. Accordingly to recent guidelines, patients with idiopathic DVT should be treated for at least 3 months and then should be evaluated for the risk-benefit ratio of long-term therapy. However, such ‘time for decision’ is often unclear and the optimal duration of VKA remains debatable. In recent studies, markers for the assessment of the individual risk for recurrent thrombosis have been proposed, which can …

medicine.medical_specialtyVitamin Kmedicine.drug_classDeep veinDrug Administration ScheduleFibrin Fibrinogen Degradation ProductsRisk FactorsNeoplasmsDrug DiscoveryD-dimerSecondary PreventionHumansMedicineUltrasonographyVenous ThrombosisPharmacologyFirst episodebusiness.industryVascular diseaseAnticoagulantAnticoagulantsresidual vein thrombosis anticoagulant therapymedicine.diseaseThrombosisSurgeryVein thrombosisVenous thrombosismedicine.anatomical_structurebusiness
researchProduct

Prolonged anticoagulant treatment in patients with cancer: Where do we stand?

2017

medicine.medical_specialtymedicine.drug_classLow molecular weight heparin030204 cardiovascular system & hematologyGastroenterology03 medical and health sciences0302 clinical medicineTinzaparinRecurrenceNeoplasmsInternal medicineHumansMedicineCancer associated thrombosisIn patientbusiness.industryLow molecular weight heparinCancer associated thrombosiBleedingAnticoagulantsCancerHematologyTinzaparinmedicine.diseaseAnticoagulant therapy030220 oncology & carcinogenesisbusiness
researchProduct

Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study.

2015

Introduction: Atrial fibrillation (AF) is associated with an increased risk of thromboembolic events. Many patients with AF receive chronic anticoagulation, either with vitamin K antagonists (VKAs) or with non-VKA oral anticoagulants (NOACs). We sought to analyze variables associated with prescription of NOAC. Methods: Patients with AF under anticoagulation treatment were prospectively recruited in this observational registry. The sample comprised 1290 patients under chronic anticoagulation for AF, 994 received VKA (77.1%) and 296 NOAC (22.9%). Univariate and multivariate analyses were performed to identify variables associated with use of NOAC. Results: Mean age was 73.8 ± 9.4 years, and 4…

MaleVitamin KClinical Decision-MakingMEDLINEAdministration OralHemorrhage030204 cardiovascular system & hematologyVitamin kanticoagulant treatment03 medical and health sciences0302 clinical medicineClinical decision makingFibrinolytic AgentsAtrial FibrillationmedicineHumansPharmacology (medical)030212 general & internal medicineAgedPharmacologyAged 80 and overbusiness.industrynonvitamin K antagonist oral anticoagulantsAnticoagulantsAtrial fibrillationMiddle Agedmedicine.diseasevitamin K antagonistsIncreased riskAnticoagulant therapyAnesthesiaOral anticoagulantFemaleCardiology and Cardiovascular Medicinebusiness
researchProduct

Antithrombotic treatment and outcomes of splanchnic vein thrombosis in an international prospective registry: Results of 2-year follow-up

2014

Abstract Background: Little information is available on the long-term clinical outcome of patients with splanchnic vein thrombosis (SVT). We aimed to assess incidence rates of bleeding, recurrence, and mortality in a large prospective cohort of SVT patients after a 2-year follow-up. Methods: Consecutive SVT patients were enrolled in a multicenter international registry, from 2008 to 2012. Information was gathered on baseline characteristics, risk factors and therapeutic strategies. Clinical outcomes (major bleeding; vascular events, defined as venous or arterial thrombosis, and mortality) during follow-up were collected and reviewed by a Central Adjudication Committee. Major bleeding was de…

medicine.medical_specialtymedicine.drug_classliver cirrhosisImmunologyanticoagulant agentBiochemistrymaleInternal medicinedeathMedicinefollow upartery thrombosishumanRisk factorProspective cohort studythrombosisriskregisteranticoagulant therapybusiness.industryhematologyIncidence (epidemiology)pathogenesisAnticoagulantCell Biologymedicine.diseasebleedingThrombosismortalitySurgeryVenous thrombosissocietySplanchnic vein thrombosisvein thrombosisrisk factorsolidincidenceantivitamin KpatientbusinessAmericanFibrinolytic agentneoplasmhospitalizationportal vein
researchProduct

Platelet Function and Coagulation in Secondary Prevention of Ischemic Heart Disease

1983

The possibility of secondary prevention. of myocardial infarction using drugs as anticoagulants and platelet antiaggregants attracted much attention in the last few years. Results obtained with anticoagulants until now, however, did not always correspond to expectations and were quite contradictory although recent studies show that such treatment is quite effective1 and also that the overall incidence of brain injuries following prolonged anticoagulant treatment does not increase: in fact a certain increase of brain haemorrhages is counterbalanced by a decrease of thrombotic events2.

Secondary preventionmedicine.medical_specialtyPlatelet Antiaggregantsbusiness.industryDiseasemedicine.diseaseAnticoagulant therapyCoagulationInternal medicineCardiologyMedicinePlateletMyocardial infarctionbusinessIschemic heart
researchProduct

Letter by Barco et al Regarding Article, "Restarting Anticoagulant Therapy After Intracranial Hemorrhage: A Systematic Review and Meta-Analysis"

2017

We read with interest the systematic review and meta-analysis authored by Murthy et al1 that appeared in Stroke . The authors studied the efficacy and safety of anticoagulant resumption after nontraumatic intracranial hemorrhage (ICH) and showed that resumption was associated with a lower risk of arterial thromboembolism but a similar risk of recurrent ICH. We do have some comments on their interpretation of the results. First, all the included studies had a retrospective design and, therefore, are characterized by heterogeneity in treatment regimens and timing of anticoagulation restart. As the authors argue in their discussion, location matters for the risk of recurrent ICH: lobar bleedin…

medicine.medical_specialtymedicine.drug_class030204 cardiovascular system & hematologyLower risk03 medical and health sciences0302 clinical medicinemedicineHumanscardiovascular diseasesIntensive care medicineStrokeAdvanced and Specialized NursingHumans; Anticoagulants; Intracranial HemorrhagesTreatment regimenbusiness.industryAnticoagulantAnticoagulantsmedicine.diseaseCausalitynervous system diseasesSurgeryAnticoagulant therapyMeta-analysisNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessIntracranial Hemorrhages030217 neurology & neurosurgeryRetrospective design
researchProduct

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

2019

Background: Appropriate antithrombotic regimens for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) are unclear. Methods: In an international trial with a two-by-two factorial design, we randomly assigned patients with atrial fibrillation who had an acute coronary syndrome or had undergone PCI and were planning to take a P2Y12 inhibitor to receive apixaban or a vitamin K antagonist and to receive aspirin or matching placebo for 6 months. The primary outcome was major or clinically relevant nonmajor bleeding. Secondary outcomes included death or hospitalization and a composite of ischemic events. Results: Enroll…

Malemedicine.medical_specialtyAcute coronary syndromeVitamin KPyridonesmedicine.medical_treatmentMEDLINEHemorrhage030204 cardiovascular system & hematologylaw.invention03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicinePharmacotherapyDouble-Blind MethodRandomized controlled triallawInternal medicineAtrial FibrillationAntithromboticmedicineHumans03.02. Klinikai orvostancardiovascular diseases030212 general & internal medicineAcute Coronary SyndromeAgedAged 80 and overAspirinbusiness.industryatrial fibrillation ; anticoagulant therapy ; acute coronary syndrome ; apixabanAnticoagulantsPercutaneous coronary interventionAtrial fibrillationGeneral MedicineMiddle Agedmedicine.diseaseConventional PCIPurinergic P2Y Receptor AntagonistsCardiologyPyrazolesDrug Therapy CombinationFemalebusinessPlatelet Aggregation InhibitorsFactor Xa InhibitorsNew England Journal of Medicine
researchProduct

Cryptogenic stroke and atrial fibrillation in a real-world population: the role of insertable cardiac monitors

2020

AbstractThe incidence of atrial fibrillation (AF) in cryptogenic stroke (CS) patients has been studied in carefully controlled clinical trials, but real-world data are limited. We investigated the incidence of AF in clinical practice among CS patients with an insertable cardiac monitor (ICM) placed for AF detection. Patients with CS admitted to our Stroke Unit were included in the study; they received an ICM and were monitored for up to 3 years for AF detection. All detected AF episodes of at least 120 sec were considered. From March 2016 to March 2019, 58 patients (mean age 68.1 ± 9.3 years, 67% male) received an ICM to detect AF after a CS. No patients were lost to follow-up. AF was detec…

Malelcsh:MedicineKaplan-Meier Estimate030204 cardiovascular system & hematologySeverity of Illness Index0302 clinical medicineRisk Factorslcsh:ScienceStrokeMultidisciplinaryIncidence (epidemiology)QRNeuro-vascular interactionsAtrial fibrillationICM deviceStrokeTreatment OutcomeCardiologyMedicineFemaleSettore MED/26 - Neurologiamedicine.symptommedicine.medical_specialtyScienceNeurophysiologyCryptogenic strokeAsymptomaticArticleProsthesis ImplantationLoop recorder03 medical and health sciencesInternal medicinemedicineHumansAgedMonitoring Physiologicbusiness.industrylcsh:RAnticoagulantsmedicine.diseaseAtrial fibrillationClinical trialCryptogenic strokeAnticoagulant therapyElectrocardiography AmbulatoryCardiac monitorslcsh:Qbusiness030217 neurology & neurosurgeryFollow-Up StudiesScientific Reports
researchProduct

Extractions without eliminating anticoagulant treatment: A literature review

2010

To establish whether there is a high enough risk of bleeding in patients who take oral anticoagulants, such that it would justify not using oral anticoagulants when performing a dental extraction, as well as if the reason for and anatomical location of the extraction increases such risk. Study We performed a bibliographic search in order to carry out a meta-analytic study using descriptive statistics. We compiled a sample of 1194 patients from the articles selected. Of these patients, a total of 2392 simple, serial surgical extractions were performed; none of the patients interrupted their anticoagulant treatment with warfarin sodium. Of the sample, 83 patients presented a certain degree of…

medicine.medical_specialtyPeriodontal pathologybusiness.industryContraindicationsmedicine.medical_treatmentIncidence (epidemiology)AnticoagulantsDentistrySoft tissue:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseSurgeryOtorhinolaryngologyDental extractionAnticoagulant therapyMaxillaHemostasisTooth ExtractionUNESCO::CIENCIAS MÉDICASHumansMedicineSurgeryPericoronitisbusinessGeneral DentistryMedicina Oral Patología Oral y Cirugia Bucal
researchProduct